Who owns Anduril? The $61B company you cannot freely trade

Key takeaways

• May 13, 2026: a $5B Series H financing established a $61B headline valuation.
• June 2025: Founders Fund invested $1B in the $2.5B Series G round, according to Reuters.
• There is no public Anduril ticker established in the records checked on October 11, 2026.
• A secondary stock quote does not establish permission to transfer the underlying shares.

What changed in 2026

The latest priced company announcement I verified is the May 13 Series H release. Thrive and a16z led the financing. A large private financing can extend the period during which a business funds itself without an exchange listing; it does not start an IPO countdown.

I separate that financing from the supplied lead about discussions near $100B. I have not substantiated a closing at that higher price in the records used for this article, so it is absent from the chart. A prospective price should replace the benchmark only when its event, terms and completion are documented.

Who owns Anduril?

This holder table is an evidence map, not a reconstructed cap table. Naming a fund as a round lead establishes participation at that date. It does not reveal all holdings bought earlier, secondary purchases, shares sold later or a current percentage. I retain the source dates beside each name.

Reuters’ June 2025 account connects Founders Fund to early backing and identifies Trae Stephens as both a cofounder and a fund partner. An overlapping person connects two institutions; it does not make them the same legal owner. I do not aggregate his undisclosed personal shares with fund holdings.

Who can actually transfer Anduril stock?

The practical ownership question is whether a buyer receives an interest the company recognizes. Anduril’s investor-relations policy describes consent requirements and rights of first refusal affecting many shares. The seller’s contract with a buyer is only one part of the process.

My read: an offer page needs to disclose what is being sold. Direct shares, a vehicle holding shares and a contract promising future proceeds create different chains of ownership. The issuer, registered holder, administrator and buyer may be different parties. A pre-IPO label cannot resolve those differences.

I would check the issuing entity, security class, registered holder, consent conditions, fees, distribution waterfall and exit rights in the actual instrument. I have not reviewed a particular retail offering here. The company policy cannot establish that every intermediary product has identical legal or economic terms.

What $5 billion of new capital actually tells us

The 2021, 2025 and 2026 observations describe transactions at $4.6B, $30.5B and $61B. My calculation puts the last value at roughly 13.3 times the first. That is a comparison of company-level transaction benchmarks across different dates, not a return earned by every shareholder. Share classes, dilution, subsequent purchases and transfer restrictions can produce very different outcomes for individual investors.

If the $61B headline is read as a post-money equity value, $5B divided by $61B is approximately 8.2%. That is a simplifying new-money ratio, not a verified ownership allocation. The release does not give each fund’s subscription, identify secondary sales or supply the fully diluted capitalization used for pricing. I therefore keep Thrive and a16z’s current stakes marked undisclosed.

A secondary-market seller may quote a price for a particular instrument. To compare it with these funding values, I would need the number of shares, the class, contractual preferences and whether the company recognizes the transfer. Anduril’s transfer policy makes that last question especially material: a quoted economic exposure and valid registered ownership can be different things.

For the IPO question, a larger financing can extend a private company’s options without fixing a listing date. I would update this investigation when a company announcement, public registration document or completed corporate transaction changes those options. A new headline suggesting a higher valuation belongs in the reported-talks category until there is evidence that the transaction happened.

How the founders built Anduril

The 2019 investor account gives a more useful starting point than the latest valuation. It names Palmer Luckey, Brian Schimpf, Matt Grimm, Joe Chen and Trae Stephens, linking their experience to Oculus, Palantir, military technology and defense investing. That combination explains how a hardware-and-software company could approach government customers while raising venture capital.

Andreessen Horowitz described a model in which Anduril financed development before selling products to government. I treat that as the investor’s description of its business model, rather than an audited conclusion about every contract. The ownership implication is straightforward: venture shareholders bear business exposure while procurement customers buy equipment and services. A government contract does not itself make the government a shareholder.

Luckey is a prominent founder; the latest financing letter identifies Schimpf as CEO. Neither fact establishes a personal ownership percentage. I apply the same distinction in who owns Cursor, where founder roles, investor backing and customers answer different questions. Individual wealth requires evidence beyond the value of the entire business.

Funding and valuation history

New capital and the price attached to the whole company are different quantities. Neither is the founder’s net worth. A founder estimate needs a substantiated stake, security rights, liabilities and actual liquidity. The financing benchmark alone supplies none of those missing inputs.

The May funding amount divided by the headline valuation is about 8.2%. That is a rough financing-size ratio, not Thrive’s stake or exact dilution. Preferred rights, option-pool changes and any secondary component can change what an individual holder owns. Share documents are needed to convert that ratio into a cap-table percentage.

A financing price is also specific to a transaction. It is not an issuer promise to buy all shares at that value. Different securities may have liquidation preferences, vesting or transfer conditions. A secondary buyer must reconcile its own terms with the rights behind the funding headline rather than assuming complete equivalence.

I count three dated priced observations, rising from $4.6B in 2021 to $61B in 2026, about 13.3 times. The 2025-to-2026 benchmark doubles. The logarithmic event bars show ratios, not daily stock prices or returns on a particular share class.

Anduril ownership timeline

Who runs Anduril?

Can you buy Anduril stock? What about an IPO?

No ordinary exchange-listed Anduril share is established by the records reviewed. A broker search result, token reference or indicative secondary price does not supply a public ticker. Our AI companies index keeps company metrics beside their dates and definitions.

The listing checks are concrete: a public offering document, an admitted security, the issuer and the offered share class. A confidential submission could exist without a public document; this review does not establish that none exists. I have no verified IPO date to put on a calendar.

Investors researching private infrastructure face similar classification problems in Crusoe’s ownership file and Lambda’s funding investigation. Completed equity, an anticipated closing and a reported future financing should produce different labels in every comparison.

Frequently asked questions

What I am watching next

Next financing: verify announcement and closing terms before adding any higher price to the chart.

Next listing milestone: check for an offering document and admitted ticker; an interview about ambitions is not a schedule.

Next ownership refresh: compare changes to issuer transfer policy and newly disclosed rights against this October 11 snapshot.

Our independent research methodology

I read the financing release and CEO letter, rendered transfer policy and contemporaneous Reuters report. I retained record dates, calculated transparent ratios and left unknown stakes and votes undisclosed. My research approach separates evidence from interpretation. I did not obtain the private shareholder register or validate a retail instrument.

Research checked 2026-10-12. Updated 2026-10-12. Meet the author and read our research approach.